In an investor update, GlaxoSmithKline (GSK) revealed its plan to promote growth and performance over next ten years.
The GlaxoSmithKline headquarters building in Brentford, west London, June 2018 [Credit: Willy Barton / Shutterstock.com].
GlaxoSmithKline (GSK) has revealed that it will be focusing on its vaccines and speciality medicines portfolio and late-stage pipeline to drive growth and create stakeholder value, following the planned demerger in mid-2022 of its Consumer Healthcare business. The company stated that the “New GSK” would be a “growth company” with “new ambitions for patients and shareholders” working to “unite science, talent and technology to get ahead of disease”.
Explore innovative, purpose-built AI solutions that elevate compliance and efficiency in quality and manufacturing operations.
17 September 2025 | 10:00 AM BST | FREE Webinar
In this webinar, find out how AI tools such as customised large language models (LLMs), orchestrated services, and human-in-the-loop design can streamline processes, enhance training, and improve efficiencies.
Can’t attend live? No worries – register to receive the recording post-event.
Emma Walmsley, Chief Executive Officer, said: “The benefits of the huge transformation we have driven since 2017 are now clear. We have strengthened our R&D and commercial execution; and transformed our group structure and capital allocation, while driving a profound cultural change with new leadership. Together, we are now ready to deliver a step-change in growth for New GSK and unlock the value of Consumer Healthcare. With world class capabilities across prevention and treatment of disease, New GSK is exceptionally well positioned to positively impact people’s health and to deliver strong performance and value to shareholders through the decade.”
Key areas of focus outlined in the investor update include:
Strategic transformation
In its investor update, the company explained how strategic transformation had already changed the business and where it could lead in the future. GSK explained that it had made major progress since 2017 in improve performance, strengthen capabilities and preparing for a new future.
GSK added that it had substantially strengthened its R&D performance and productivity, delivering 11 major product approvals since 2017 and doubled the number of assets in Phase III and registration to 22. Additionally, its commercial execution was transformed with new and specialty products now reaching £10 billion in annual sales. Meanwhile changes to the group’s portfolio and network within vaccines and pharma have led to annual cost savings delivery of £0.5 billion and proceeds from divestment of non-core brands of £1.4 billion. The company also stated that two global mergers had radically transformed its portfolio.
Maximising vaccines and specialty medicines
New GSK will prioritise R&D and commercial investment in vaccines and specialty medicines, which are expected to grow to around three-quarters of company sales by 2026. As part of its 2021-26 outlook, vaccines is expected to grow sales at a high single-digit percent CAGR and specialty medicines at a double-digit percent CAGR.
The company is focused across four core therapeutic areas (TAs): Infectious Diseases, HIV, Oncology and Immunology/Respiratory. In addition, New GSK will remain open to opportunities outside these core TAs where there are scale opportunities rooted in immune science and genetic validation.
The company currently has a pipeline of 20 vaccines and 42 medicines – many of which are potential best or first in class opportunities.
Optimising general medicines
A newly defined general medicines product group will contain all of New GSK’s primary care brands, including older established products as well as the inhaled respiratory portfolio. General medicines will have differing performance profiles by region and brand, with growth expected most in emerging markets.
General medicines will be optimised for profitability and cash generation to support investment in vaccines and specialty medicines. As part of this approach, further streamlining of the portfolio is expected through divestment or partnering of non-priority brands.
Environmental and social governance (ESG)
New GSK said maintaining its “sector leading” ESG performance will be an integral part of the strategy.
The company intends to take a focused approach to ESG, prioritising resources across six key areas: pricing/access, global health, inclusion and diversity, the environment, product governance and operating standards.
Accountabilities for these six areas will be at executive level and New GSK expects to further strengthen the alignment of incentives and remuneration to delivery of ESG performance, with increased visibility in corporate reporting.
A critical measure of success for New GSK will be health impact at scale. The company expects to positively impact the health of more than 2.5 billion people around the world over the next 10 years.
Financial outlooks
2021-2026 outlook
Over the next five-year period, New GSK expects to deliver sales growth and adjusted operating profit growth of more than five and more than 10 percent compound annual growth rates (CAGR), respectively. This growth is expected to be underpinned by a combination of strong revenue growth from new vaccines and specialty medicines, improving operational performance and benefits from the transformation of recent years.
The company also expects to improve adjusted operating margin from the mid-20 percent range in 2021 to over 30 percent by 2026. Improved sales growth, sales mix benefits and realisation of cost savings from previously announced programmes are all expected to contribute to margin improvements.
2026-2031 ambition
By 2031, New GSK aims to deliver sales of more than £33 billion, despite the anticipated loss of exclusivity for dolutegravir in 2028/29. Achievement of this ambition is driven by commercial execution of New GSK’s current late-stage pipeline. The company estimates that certain assets in late-stage development have the potential in aggregate to deliver peak year sales of more than £20 billion on a non-risk adjusted basis.
The £33 billion sales ambition is before any significant revenue contribution from early-stage pipeline assets or any contribution from business development.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.